PDF(Pubmed)
Abstract：
Non-classical HLA restricted T cell subsets such as γδ T and NK-T cells are showing promises for immune-based therapy of hematological malignancies. Mucosal-Associated Invariant T cells (MAIT) belong to this family of innate-like T cell subsets and are the focus of many studies on infectious diseases, owing to their unusual recognition of bacterial/fungal metabolites. Their ability to produce type 1 cytokines (IFNγ, TNFα) as well as cytotoxic effector molecules endows them with potential anti-tumor functions. However, their contribution to tumor surveillance in solid cancers is unclear, and only few studies have specifically focused on MAIT cells in blood cancers. In this review, we wish to recapitulate our current knowledge on MAIT cells biology in hematological neoplasms, at diagnosis and/or during treatment, as well as tentative approaches to target them as therapeutic tools. We also wish to take this opportunity to briefly elaborate on what we think are important question to address in this field, as well as potential limitations to overcome in order to make MAIT cells the basis of future, novel therapies for hematological cancers.
摘要：
非经典HLA限制性T细胞亚群如γδT和NK-T细胞显示了血液恶性肿瘤的基于免疫的治疗的希望。粘膜相关不变T细胞（MAIT）属于先天性T细胞亚群家族，是许多感染性疾病研究的重点，由于它们对细菌/真菌代谢物的不寻常识别。它们产生1型细胞因子的能力(IFNγ，TNFα）以及细胞毒性效应分子赋予它们潜在的抗肿瘤功能。然而,它们对实体癌肿瘤监测的贡献尚不清楚，只有少数研究专门针对血癌中的MAIT细胞。在这次审查中,我们希望概述我们目前对血液肿瘤MAIT细胞生物学的了解，在诊断和/或治疗期间，以及将它们作为治疗工具的暂定方法。我们还希望借此机会简要阐述我们认为在这一领域需要解决的重要问题，以及为了使MAIT细胞成为未来的基础而需要克服的潜在限制，血液肿瘤的新疗法。
